Plus   Neg

QIAGEN Q2 Profit Tops Estimates; Sales Up 16%

QIAGEN N.V. (QGEN) reported that its second quarter adjusted earnings per share increased to $0.55 ($0.56 CER), from $0.33, last year. On average, ten analysts polled by Thomson Reuters expected the company to report profit per share of $0.46, for the quarter. Analysts' estimates typically exclude special items.

Second quarter total net sales rose 16% to $443.3 million from $381.6 million, last year. Growth was 19% at constant exchange rates (CER). Analysts expected revenue of $425.82 million for the quarter.

"The unprecedented demand for products used in coronavirus testing is driving QIAGEN's performance in 2020," said Thierry Bernard, CEO of QIAGEN N.V.

QIAGEN Boards have reaffirmed unanimous recommendation that the company's shareholders accept Thermo Fisher Offer and tender their shares on or before August 10.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amid the growing climate crisis, Walmart said it is raising its ambition to zero emissions by 2040, without the use of carbon offsets, across its global operations. The retail giant, along with the Walmart Foundation, also committed to help protect, manage or restore at least 50 million acres of land and one million square miles of ocean by 2030. The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020.
Follow RTT